Should we catheterize all patients with unstable angina? No—only the ones with coronary artery disease∗∗Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.  by Kussmaul, William G
EDITORIAL COMMENT
Should We Catheterize All
Patients With Unstable
Angina? No—Only the Ones
With Coronary Artery Disease*
William G. Kussmaul III, MD, FACC
Philadelphia, Pennsylvania
In this issue of the Journal, Solomon et al. (1) have afforded
us another look at the venerable Thrombolysis In Myocar-
dial Infarction trial (TIMI)-IIIB dataset. The results cast
useful light on an ongoing debate concerning how best to
treat patients who present with unstable angina or non–Q-
wave myocardial infarction (MI)—conditions now recog-
nized to represent a spectrum, and combined under the
rubric “acute coronary syndromes” (ACS).
The Solomon et al. (1) study is an analysis of patient
subsets from TIMI-IIIB, originally published in 1994 (2).
See page 969
The TIMI-IIIB trial recruited patients from 1989 to 1992,
before the era of stents or platelet IIB/IIIA receptor
blockers. Patients were required to have experienced chest
pain at rest within 24 h prior to enrollment. That the chest
pain represented myocardial ischemia was attested by isch-
emic electrocardiographic (ECG) changes, history of prior
infarction, previously documented coronary stenosis or an
abnormal stress thallium scan result. Eligible, consenting
patients were randomized to intravenous tissue-type plas-
minogen activator or placebo, and also to a conservative
versus an early invasive management strategy. Some 98% of
patients assigned to the invasive arm underwent coronary
angiography, and 63% underwent subsequent coronary re-
vascularization (25% coronary artery bypass graft surgery;
38% percutaneous transluminal coronary intervention
[PTCI]). Of the conservative group, 64% underwent cath-
eterization for clinical indications; 50% also had coronary
revascularization. The combined end points included death,
MI, or a stress test showing ischemia at six weeks’ follow-
up. The overall trial results were negative both for fibrino-
lytic therapy and for the early invasive strategy, although the
patients in the latter group did experience shorter hospital
stay, fewer episodes of rehospitalization and required less
antianginal drug therapy.
These results were interpreted to indicate that routine
catheterization was not indicated in patients presenting with
ACS. However, although TIMI-IIIB was a model clinical
trial in many ways, a plausible criticism is that the somewhat
loose definition of “myocardial ischemia” may have allowed
for the inclusion of patients at very low risk, and even some
who did not have coronary artery disease (e.g., a patient with
rest pain and an abnormal thallium result, who was subse-
quently shown to have normal coronary arteries). In such
patients, the procedural risk of catheterization might out-
weigh the potential for benefit.
The current report (1) reanalyzes TIMI-IIIB from this
viewpoint, taking into account certain clinical factors that
are readily available upon presentation to the hospital.
Multivariate analysis yields four independent prognostic
factors: older age, ST-segment depression at presentation,
“complicated angina” and elevated baseline creatine
kinase-MB fraction. A schema is derived that separates the
patients into five tiers of risk, of which the top two appear
to have significantly benefited from routine catheterization
and intervention, whereas the lower three were not helped
(or possibly may have been harmed) by catheterization and
intervention as practiced in the late 1980s. Another way to
state their findings would be: Among patients presenting
with chest pain, those who have unstable coronary artery
disease are most likely to benefit from invasive management.
The concept of multivariate risk stratification is hardly
new (3–11). Examination of the results of these earlier
studies shows that ischemic ECG changes at presentation,
advanced age and elevated cardiac enzyme markers have
been repeatedly identified as significant negative prognostic
factors in patients with ACS. The Solomon et al. study (1)
goes further, offering treatment and outcome data showing
the utility of risk stratification.
Why were C-reactive protein levels not predictive of
short-term prognosis? Other studies have shown the con-
trary (12,13). Surprisingly also, smoking status and diabetes
did not enter into this multivariate predictive model.
What makes multivariate risk stratification more than a
dry intellectual exercise? The answer depends entirely on
whether we have any effective means of altering the short-
term prognosis of ACS patients for the better. Clearly, we
do. The effectiveness of antithrombotic agents has been
repeatedly shown, including aspirin, heparin, low-
molecular-weight heparins, platelet IIB/IIIA receptor an-
tagonists and, most recently, thienopyridines, although the
optimum combination of these agents has not yet been
determined. Fibrinolytic agents do not confer benefit in
non–ST-elevation ACS.
Invasive management would certainly make sense. After
all, the reason an ACS is an acute syndrome is that a
pre-existent atherosclerotic plaque has become associated
with fresh thrombus. Removing this complex blockage and
restoring nutritive blood flow is logical, and arguing against
it would appear counterintuitive. The feasibility of acute
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angioplasty for ACS was shown more than 15 years ago
(14–18). The question is: To which patients is an aggressive
approach best applied? The American College of Cardiology/
American Heart Association guidelines for management of
ACS (19) suggest very wide latitude in determining who is an
appropriate candidate for an early invasive strategy. A debate
continues on this point in the literature. Recent studies
(VANQWISH [20], FRISC-II [21] and now TACTICS/
TIMI-18 [22]) sound apparently contradictory notes. The
overall results of Veterans Affairs Non–Q-Wave Infarction
Strategies in Hospital (VANQWISH) suggested that an early
invasive approach would be harmful. Both Fragmin and Fast
Revascularization during Instability in Coronary Artery Dis-
ease (FRISC-II) and TACTICS/TIMI-18 came to opposite
conclusions. It makes sense that the differences among these
trials may be explained by the inclusion of higher-risk patients
in the latter two trials, a concept that is supported by the
present reanalysis of TIMI-IIIB.
If the higher-risk ACS patients are good candidates for
invasive management, what about the others? The possible
harm resulting from an invasive strategy in low-risk TIMI-
IIIB patients may be explained in part by the simultaneous
administration of fibrinolytic therapy to some of these
patients. Coronary intervention after full-dose lytic therapy
is now recognized as a “salvage” procedure in acute MI, a
situation associated with higher procedural risk than PTCI
without prior fibrinolysis. Yet perhaps not coincidentally,
the lowest-risk patients in VANQWISH, FRISC-II and
TACTICS may also have done worse with an early invasive
strategy. Many of these patients were troponin-negative. An
open-season catheterization approach to patients with ACS
who lack high-risk features is probably inappropriate.
The limitations of the Solomon et al. study (1) are several,
and they are well outlined in the report. The post hoc nature
of the analysis and the decade-old vintage of the data urge
caution in the interpretation of the results; yet their con-
cordance with the outcome of recent randomized prospec-
tive trials is striking. What seems clear, based on the present
study as well as the results of FRISC-II and TACTICS, is
that a nihilistic approach with regard to early invasive study
in patients with ACS is not warranted. The evidence presented
in the current study supports the concept that higher-risk
patients, at least those with clear-cut ECG changes of ischemia
or elevated cardiac enzyme markers, should undergo early
angiography and revascularization. Thus, the subtitle of this
editorial is only slightly tongue-in-cheek.
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